Directors
Andrés Poveda
Fundación Instituto Valenciano de Oncología, Valencia, Spain
Jan B. Vermorken
Antwerp University Hospital, Edegem, Belgium

Scientific Committee
Andrés Cervantes (ESMO, GEICO)
Antonio González (ESMO, GEICO)
Andrés Poveda (ESMO, GEICO)
Jan B. Vermorken (ESMO, GEICO)

Venue
Palau de la Música
Paseo de la Alameda, 30
46023 Valencia, Spain

Language
The official language of the symposium is English. Simultaneous translation into Spanish will be provided.

Symposium secretariat
E-mail: aocsymp2015@doctaforum.com

www.valencia-ovariancancersymp.org
Directors
Andrés Poveda
Fundación Instituto Valenciano de Oncología, Valencia, Spain
Jan B. Vermorken
Antwerp University Hospital, Edegem, Belgium

Scientific Committee
Andrés Cervantes (ESMO, GEICO)
Antonio González (ESMO, GEICO)
Andrés Poveda (ESMO, GEICO)
Jan B. Vermorken (ESMO, GEICO)

Venue
Palau de la Música
Paseo de la Alameda, 30
46023 Valencia, Spain

The official language of the symposium is English. Simultaneous translation into Spanish will be provided.

Symposium secretariat
E-mail: aocsymp2015@doctaforum.com
www.valencia-ovariancancersymp.org

10th International Symposium
Advanced Ovarian Cancer: Optimal Therapy Update
Valencia, Spain, 6th March 2015
10th International Symposium 
Advanced Ovarian Cancer 
Optimal Therapy Update

Valencia, Spain, 6th Mar 2015

SESSION - 3 INNOVATIONS IN THE APPROACH TO BORDERLINE TUMORS AND EPHITHELIAL OVARIAN CANCER
Chair: Jonathan A. Berek
10:30 - 10:50 Advances in targeted therapy for ovarian cancer
10:30 - 10:50 Michael A. Bookman, University of Arizona Cancer Center, Tucson (AZ), USA
10:50 - 11:00 Discussions
11:00 - 11:20 Coffee break

SESSION - 3 CLINICAL IMPACT OF TARGETED THERAPIES
Chair: Andrés Poveda, University Medical Center Groningen, Groningen, The Netherlands
11:45 - 12:00 Antiangiogenic agents
12:00 - 12:20 Bradford W. Lotze, University of California, San Francisco, CA, USA
12:20 - 12:40 PIF-0058
12:40 - 12:50 Giovanna Giudici, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil
12:50 - 13:10 Discussione
13:10 - 13:30 Lunch

SESSION - 4 DIFFERENTIATED APPROACH TO EPITHELIAL OVARIAN CANCER
Chair: Doughty A. Leong, University of Iowa Hospitals and Clinics, Iowa City, IA, USA
15:00 - 15:20 Low grade serous
15:20 - 15:40 Chadwick W. Donnell, Memorial Sloan Kettering Cancer Center, New York (NY), USA
15:40 - 16:00 Discussions
16:00 - 16:20 Coffee break

SESSION - 5 STANDARD OF CARE OF OVARIAN CANCER IN 2015
Chair: Andrés Cervantes, Hospital Clínico San Carlos, Madrid, Spain
16:30 - 17:00 Maintenance therapy in non-selected histotypes
16:30 - 16:50 David M. Gershenson, The University of Texas MD Anderson Cancer Center, Houston (TX), USA
16:50 - 17:10 Sander K. van der Hegge, Kliniken Essen-Mitte, Essen, Germany
17:10 - 17:30 Discussions
17:30 - 17:50 Lunch

SESSION - 5 DIFFERENTIATED APPROACH TO ENTHUSIASTIC OVARIAN CANCER
Chair: Doughty A. Leong, University of Iowa Hospitals and Clinics, Iowa City, IA, USA
17:00 - 17:30 Primary disease
17:00 - 17:20 Michael A. Bookman, University of Arizona Cancer Center, Tucson (AZ), USA
17:20 - 17:40 Recurrent disease
17:40 - 17:50 M. Rebecchi, Hospital Dig. Pete. Forlì, Forlì
17:50 - 18:10 Patient reported outcomes in ovarian cancer (Dr. Tikals)
18:10 - 18:30 Discussions
18:30 - 18:45 Coffee break

SESSION - 6 REMINDERS AND CONCLUSIONS
Chair: Antonio Mirandés, Fundación Instituto Valenciano de Oncología, Valencia, Spain
18:45 - 18:50 Remarks and conclusions
10th International Symposium
Advanced Ovarian Cancer
Optimal Therapy Update

Valencia, Spain, 6th March 2015

SESSION 1
CRITICAL ISSUES FOR FURTHER DEVELOPMENT IN OVARIAN CANCER

08:45 - 09:25  Keynote Lecture: Progress in the treatment of ovarian cancer. Lessons from Homologous Recombination Deficiency
Ignacio Romero, Chuan Liu, Lana Kandalaft, Michael J. Birrer, Douglas A. Levine, Ludwig Institute for Cancer Research, Centre Hospitalier Universitaire Vaudois, The Royal Marsden Hospital, Sutton, Surrey, United Kingdom
Massachusetts General Hospital, Boston (MA), USA

11:35 - 11:45  Discussion
Sven Mahner, Sven Schmid, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

SESSION 2
INNOVATIONS IN THE APPROACH TO BORDERLINE TUMORS

09:25 - 09:45  The molecular genetics of epithelial ovarian cancer
Michael J. Birrer, Memorial Sloan Kettering Cancer Center, New York (NY), USA

10:05 - 10:20  Molecular pathology of borderline tumors
Sergi Martínez, Servei de Patologia Oncològica, Institut d’Investigació Biomèdica de Bellvitge, Barcelona, Spain

10:35 - 10:55  Optimal approach to borderline tumors
Diana D. Casal, Hospital Clínico Universitario de Valencia, Valencia, Spain

10:55 - 11:15  Molecular imaging in invasive ovarian carcinoma
Andreas Du Bois, University Medical Center Groningen, Groningen, The Netherlands

11:15 - 11:30  Neo adjuvant chemotherapy in ovarian cancer revisited?
Anais Malpica, The University of Texas MD Anderson Cancer Center, Houston (TX), USA

11:35 - 11:50  Discussion
Andrés Cervantes, Finsen Institute, University of Copenhagen, Copenhagen N, Denmark; Jan B. Vermorken, Klinikum Essen-Mitte, Essen, Germany

SESSION 3
CLINICAL IMPACT OF TARGETED THERAPIES

11:50 - 12:05  Maintenance therapy in non-selected histotypes
David M. Gershenson, The University of Texas MD Anderson Cancer Center, Houston (TX), USA

12:05 - 12:30  Antiangiogenic agents
Bradley W. Monk, St. Joseph’s Hospital and Medical Center, Phoenix (AZ), USA

12:15 - 12:30  PARP inhibitors
Michael A. Bookman, Memorial Sloan Kettering Cancer Center, New York (NY), USA

12:30 - 12:45  Discussion
Michael Friedlander, Memorial Sloan Kettering Cancer Center, New York (NY), USA

13:30 - 13:45  Coffee break

SESSION 4
DIFFERENTIATED APPROACH TO EPITHELIAL OVARIAN CANCER

13:45 - 14:00  High order serous carcinoma
Thomas Perren, University College London Cancer Institute, London, United Kingdom

14:00 - 14:15  Mucinous tumors
Timothy Fleming, Vanderbilt-Ingram Cancer Center and Pathology, Vanderbilt University Hospital, Nashville, USA

14:15 - 14:30  Clear cell tumors
Stefan Flentje, Klinikum Essen-Mitte, Essen, Germany

14:30 - 14:45  Low grade serous
Isabelle Ray-Coquard, Gynecologic Oncology Center, Kiel, Germany

14:45 - 15:00  Discussion
Antonio González, Instituto Valenciano de Oncología, Valencia, Spain; Andrés Poveda, Gynecologic Oncology Center, Barcelona, Spain

SESSION 5
STANDARD OF CARE OF OVARIAN CANCER IN 2015

15:00 - 15:15  Primary disease
Michael Friedlander, Memorial Sloan Kettering Cancer Center, New York (NY), USA

15:15 - 15:30  Surgery
Timothy Fleming, Vanderbilt-Ingram Cancer Center and Pathology, Vanderbilt University Hospital, Nashville, USA

15:30 - 15:45  Maintenance therapy in non-selected histotypes
Michael A. Bookman, Memorial Sloan Kettering Cancer Center, New York (NY), USA

15:45 - 16:00  Discussion
Eric Pujade-Lauraine, Fondation Institut de Veïnciana de Oncologia, Valencia, Spain; David R. Spriggs, Department of Obstetrics and Gynecology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; David M. Gershenson, The University of Texas MD Anderson Cancer Center, Houston (TX), USA; Sandro Pignata, Hôpital Lippe, Naples, Italy

SESSION 6
DIFFERENTIATED APPROACH TO EPITHELIAL OVARIAN CANCER

16:00 - 16:15  Low grade serous
David M. Gershenson, The University of Texas MD Anderson Cancer Center, Houston (TX), USA

16:15 - 16:30  Clear cell tumors
Timothy Fleming, Vanderbilt-Ingram Cancer Center and Pathology, Vanderbilt University Hospital, Nashville, USA

16:30 - 16:45  Discussion
Antonio González, Instituto Valenciano de Oncología, Valencia, Spain; Andrés Poveda, Gynecologic Oncology Center, Barcelona, Spain

16:45 - 17:00  Remarks and conclusions
Sven Schmid, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
SESSION 1 CRITICAL ISSUES FOR FURTHER DEVELOPMENT IN OVARIAN CANCER
08:30 - 08:45 Welcome
Lana Kandalaft, Michael J. Birrer, Stanley B. Kaye, Douglas A. Levine, Ludwig Institute for Cancer Research, Centre Hospitalier Universitaire Vaudois, The Royal Marsden Hospital, Sutton, Surrey, United Kingdom

08:45 - 09:05 The molecular genetics of epithelial ovarian cancer
Jonathan A. Ledermann, Chairs:
leadership roles, the importance of multidisciplinary teams, and the role of healthcare professionals

09:05 - 09:25 Immunology
Jan B. Vermorken, Chairs:
the role of immune checkpoint inhibitors in ovarian cancer, the impact of the tumor microenvironment, and the future of immunotherapy in ovarian cancer

09:25 - 09:45 Other targeted agents
Michael A. Bookman, Chairs:
advancements in targeted therapies, the role of PARP inhibitors, and the future of targeted agents in ovarian cancer

10:05 - 10:15 Coffee break

SESSION 2 INNOVATIONS IN THE APPROACH TO BORDERLINE TUMORS
10:15 - 10:35 Molecular pathology of borderline tumors
Sergi Martínez, Chairs:
advancements in molecular pathology of borderline tumors, the role of genetic testing in borderline tumors, and the impact of molecular pathology on management of borderline tumors

10:35 - 10:55 Optimal approach to borderline tumors
Sven Mahner, Chairs:
the role of optimal management strategies, the impact of neoadjuvant chemotherapy on borderline tumors, and the role of clinical and histological criteria in the management of borderline tumors

11:15 - 11:35 Neo adjuvant chemotherapy in ovarian cancer revisited?
An Reyners, Chairs:
advancements in neoadjuvant chemotherapy for ovarian cancer, the impact of new agents and combination therapies, and the role of biomarkers in the selection of patients for neoadjuvant chemotherapy

11:35 - 11:45 Discussion

SESSION 3 CLINICAL IMPACT OF TARGETED THERAPIES
11:45 - 12:00 Mucinous tumors
Andreas Du Bois, Chairs:
advancements in the management of mucinous ovarian cancer, the role of targeted therapies in mucinous tumors, and the impact of treatment strategies on survival and quality of life

12:00 - 12:15 Adjuvant/Neoadjuvant agents
Bradley H. White, Chairs:
advancements in adjuvant/neoadjuvant therapies for ovarian cancer, the role of targeted agents in adjuvant therapy, and the impact of biomarkers on the selection of targeted agents

12:15 - 12:30 PARP inhibitors
Jonathan A. Ledermann, Chairs:
advancements in PARP inhibitors for ovarian cancer, the impact of new PARP inhibitors on treatment options, and the role of biomarkers in the selection of patients for PARP inhibitors

12:30 - 12:45 Other targeted agents
David M. Gershenson, Chairs:
advancements in other targeted agents for ovarian cancer, the role of new agents in treatment strategies, and the impact of combination therapies on outcomes

12:45 - 13:00 Discussion

SESSION 4 DIFFERENTIATED APPROACH TO EPITHELIAL OVARIAN CANCER
13:00 - 13:15 Low grade serous
Sandro Pignata, Chairs:
advancements in the management of low grade serous ovarian cancer, the role of targeted therapies in low grade serous tumors, and the impact of treatment strategies on survival and quality of life

13:15 - 13:30 Clear cell tumors
Antonio González, Chairs:
advancements in the management of clear cell ovarian cancer, the role of targeted therapies in clear cell tumors, and the impact of treatment strategies on survival and quality of life

13:30 - 13:45 Mucinous tumors
Jan B. Vermorken, Chairs:
advancements in the management of mucinous ovarian cancer, the role of targeted therapies in mucinous tumors, and the impact of treatment strategies on survival and quality of life

13:45 - 14:00 Discussion

SESSION 5 STANDARD OF CARE OF OVARIAN CANCER IN 2015
14:00 - 14:15 Primary disease
Michael Friedlander, Chairs:
advancements in the management of primary ovarian cancer, the role of targeted therapies in primary disease, and the impact of treatment strategies on survival and quality of life

14:15 - 14:30 Recurrent disease
Bradley H. White, Chairs:
advancements in the management of recurrent ovarian cancer, the role of targeted therapies in recurrent disease, and the impact of treatment strategies on survival and quality of life

14:30 - 14:45 Remarks and conclusions
Andrés Cervantes, Chairs:
advancements in the management of ovarian cancer, the role of targeted therapies in the management of ovarian cancer, and the impact of treatment strategies on survival and quality of life

14:45 - 15:00 Patient reported outcomes in ovarian cancer clinical trials. Missed opportunities
Eric Pujade-Lauraine, Chairs:
advancements in patient reported outcomes in ovarian cancer clinical trials, the role of patient reported outcomes in clinical decision making, and the impact of patient reported outcomes on the management of ovarian cancer

15:00 - 15:15 Maintenance therapy in non-selected patients
Jaci Siegel-Pfister, Chairs:
advancements in maintenance therapy in non-selected patients, the role of targeted therapies in maintenance therapy, and the impact of treatment strategies on survival and quality of life

15:15 - 15:45 Love and status
David M. Gershenson, Chairs:
advancements in love and status, the role of targeted therapies in love and status, and the impact of treatment strategies on survival and quality of life

15:45 - 16:00 Maintenance therapy in recurrent patients
Michael A. Bookman, Chairs:
advancements in maintenance therapy in recurrent patients, the role of targeted therapies in maintenance therapy, and the impact of treatment strategies on survival and quality of life

16:00 - 16:30 Discussion

16:30 - 16:45 Coffee break

SESSION 6 DIFFERENTIATED APPROACH TO EPITHELIAL OVARIAN CANCER
16:45 - 17:00 Primary disease
Michael Friedlander, Chairs:
advancements in the management of primary ovarian cancer, the role of targeted therapies in primary disease, and the impact of treatment strategies on survival and quality of life

17:00 - 17:15 Recurrent disease
Bradley H. White, Chairs:
advancements in the management of recurrent ovarian cancer, the role of targeted therapies in recurrent disease, and the impact of treatment strategies on survival and quality of life

17:15 - 17:30 Remarks and conclusions
Andrés Cervantes, Chairs:
advancements in the management of ovarian cancer, the role of targeted therapies in the management of ovarian cancer, and the impact of treatment strategies on survival and quality of life

17:30 - 17:45 Maintenance therapy in non-selected patients
Jaci Siegel-Pfister, Chairs:
advancements in maintenance therapy in non-selected patients, the role of targeted therapies in maintenance therapy, and the impact of treatment strategies on survival and quality of life

17:45 - 18:00 Maintenance therapy in recurrent patients
Michael A. Bookman, Chairs:
advancements in maintenance therapy in recurrent patients, the role of targeted therapies in maintenance therapy, and the impact of treatment strategies on survival and quality of life

18:00 - 18:15 Discussion

18:15 - 18:30 Remarks and conclusions
Andrés Cervantes, Chairs:
advancements in the management of ovarian cancer, the role of targeted therapies in the management of ovarian cancer, and the impact of treatment strategies on survival and quality of life

18:30 - 18:45 Coffee break

18:45 - 19:00 Remarks and conclusions
Andrés Cervantes, Chairs:
advancements in the management of ovarian cancer, the role of targeted therapies in the management of ovarian cancer, and the impact of treatment strategies on survival and quality of life

19:00 - 20:00 Remarks and conclusions
Andrés Cervantes, Chairs:
advancements in the management of ovarian cancer, the role of targeted therapies in the management of ovarian cancer, and the impact of treatment strategies on survival and quality of life
Directors
Andrés Poveda
Fundación Instituto Valenciano de Oncología, Valencia, Spain
Jan B. Vermorken
Antwerp University Hospital, Edegem, Belgium

Scientific Committee
Andrés Cervantes (ESMO, GEICO)
Antonio González (ESMO, GEICO)
Andrés Poveda (ESMO, GEICO)
Jan B. Vermorken (ESMO, GEICO)

Organized by Under the Auspices of
Valencia, Spain, 6th March 2015
International Symposium
Advanced Ovarian Cancer
Optimal Therapy. Update
Venue
Palau de la Música
Paseo de la Alameda, 30
46023 Valencia, Spain
Language
The official language of the symposium is English.
Simultaneous translation into Spanish will be provided.
Symposium secretariat
E-mail: aocsymp2015@doctaforum.com
www.valencia-ovariancancersymp.org